ANNEE 2011

Publié le 09/02/2012 à 14h02 (mis à jour le 11/09/2015 à 11h39)

PHARMACOLOGIE CLINIQUE

Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical angiographic and genetic factors associated with early coronary stent thrombosis. JAMA 2011, 306, 1765-1774.

Cochen De Cock V, Debs R, Oudiette D, Leu S, Radji F, Tiberge M, Yu H, Bayard S, Roze E, Vidailhet M, Dauvilliers Y, Rascol O, I Arnulf. The improvement of movement and speech during rapid eye movement sleep behaviour disorder in Multiple System Atrophy. Brain 2011, 10, 1-7.

Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. Wearing-off scales in Parkinson’s disease : critique and recommendations. Mov Disord 2011, 26, 2169-2175.

Eriksson Dornellof M, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson’s disease. Mov Disord 2011,12, 2183-2189.

Fuzier R, Maguès JP, Dupuis E, Pomiès S, Segui S, Sénard JM. Inhibiteurs de la pompe à protons : impact d’une évaluation des pratiques professionnelles sur la pertinence des prescriptions. ANNFAR 2011, 30, 814-818.

Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honoré A, Rivaud S, Vidailhet M, Dürr A, Brice A ; French Parkinson’s Disease Genetics Study Group. Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease. Hum Mol Genet. 2011, 20, 202-210.

Maret D, Caussé E, Lapeyre-Mestre M, Mansuy JM, Delisle MB, Courtade M, Linas MD, Telmon N, Sixou M, Astié F, Grimoud AM. Prélèvements buccaux en pratique clinique. Médecine buccale 2011, 28, 250.

Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz GG, Schrag A. Health-related quality-of-life scales in Parkinson’s disease : Critique and recommendations. Mov Disord 2011, 26, 2371-80.

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM,Tison F, Bezard E. Priorities in Parkinson’s disease research. Nat Rev Drug Discov 2011, 10, 377-393.

Moulis G, Astudillo, L, Pugnet G, Sailler L, Arlet P. Tuberculose cutanée de l’adulte immunocompétent. Med Mal Inf 2011. 41, 663-664.

Moulis G, Delavigne K, Alvarez M, Brassat D, Bonneville F, Massip P, Adoue D. Des céphalées chroniques. Rev Med Int 2011. 32, 46-47.

Moulis G, Delavigne K, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. Profil des anticorps antiphospholipides et risque de thrombose : étude comparative entre thrombopénie immunologique chronique et syndrome des antiphospholipides primaire. Rev Med Int 2011. 32, 724-29.

Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftmann S, Tison F, Wenning G, Goetz C, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O. The Movement Disorders Task Force on review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011, 26, 1985-92.

Perez Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson’s disease. Expert Rev Neurother 2011, 11, 925-35.

Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf 2011, 10, 633-643.

Radaideh GA, Choueiry P, Eid E, Ismail A, Berrou JP, Sedefdjian A, Sévenier F, Pathak A. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function : analysis of middle east data from the OSCAR study. Vascular Health and Risk Management 2011, 7, 1-5.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F,Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10, 415-423.

Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson’s disease – Therapeutics. Mov Disord 2011, 6, 1072-1082.

Rascol O. Drugs and drug delivery in PD : optimizing control of symptoms with pramipexole prolonged-release. Eur. J. Neurol 2011, 18, 3-10.

Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, Van de Witte SV, Theeuwes A. for the Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson’s disease : results from two large randomized, double-blind trials. Mov Disord 2011, 26, 1464-1476.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W MD. in the name of the pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson’s disease : a randomized controlled trial. Neurology 2011, 8, 767-74.

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement disorder society evidence-based medicine review update : treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011, 26, S42-S80.

Smih F, Desmoulin F, Berry M, Turkieh A, Harmancey R, Iacovoni J, Trouillet C, Delmas C, Pathak A, Lairez O, Koukoui F, Massabuau P, Ferrieres J, Galinier M, Rouet P. Blood signature of pre-heart failure : a microarrays study. Plos One 2011, 6, 2041.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Drug prescribing before and during pregnancy in south west France. Drug Saf 2011, 34, 595-604.

Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France : a study using the French PharmacoVigilance database. BMC Clin Pharmacol 2011, 11,5.

Bismuth M, Oustric S, Boyer P, Escourrou B, Brillac T, Mesthe P, Boutin A, Arlet P, Montastruc JL. La pharmacie phamiliale : enquête auprès d’un échantillon de patients en Midi-Pyrénées. Thérapie 2011, 66, 131-134.

Bismuth S, Laing-Leng E, Oustric S, Montastruc JL, Lapeyre-Mestre M. Quels antalgiques après le retrait du dextropropoxyphène ? Enquête auprès de médecins généralistes de la région Midi-Pyrénées. Thérapie 2011, 66, 25-28.

Bœuf-Cazou O, Bongue B, Ansiau D, Marquié JC, Lapeyre-Mestre M. Impact of long-term benzodiazepine use on cognitive functioning in young adults : the VISAT cohort. Eur J Clin Pharmacol 2011, 67, 1045-52.

Bœuf-Cazou O, Lapeyre-Mestre M, Niezborala M, Montastruc JL. Profil de consommation de substances psychoactives dans le milieu du travail : résultats de l’enquête "mode de vie et travail". Thérapie 2011, 66, 155-165.

Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism : a review of 17 years experience in a regional pharmacovigilance center in France. Mov Disord 2011, 12, 2226-31.

Bondon-Guitton E, Prévot G, Didier A, Montastruc JL. Pulmonary arterial hypertension and benfluorex : 5 case reports. Thérapie 2011, 66, 135-136.

Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-jais C, Castot A, Montastruc JL and French Network of PharmacoVigilance Centres (CRPV) : Autret-Leca E, Baldin B, Bavoux F, Bénard-laribière A, Biour M, Beyens MN, Colin F, Coquerel A, Crepin S, Décréau-Gaillon G, Dos Santos S, Efthekhari P, Favrelière S, Gautier S, Gras-Champel V, Javot L, Jean-Pastor MJ, Le Beller C, Lebrun-Vignes B, Millaret A, Perrazi A, Pinzani V, Riché C, Schir E, Sgro C, Tebacher-Alt M, Trenque T, Valnet-Rabier MB, Veyrac G . Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2011, 67, 649-651.

Castel M, Pathak A, Despas F, Mazières J. Adverse effects of new biological therapies for non-small-cell bronchial cancer. Presse Médicale 2011, 40, 415-419.

Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, on behalf of the EULEV study group (Vespignani H, Marchal C, Alpérovitch A, Bénichou J, Jager A, Lavernhe G, Mann M, Montastruc JL, Pédespan JM). The EULEV cohort study : rates of and factors associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol 2011, 1, 121-7.

Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy hypertension : An International Journal of Women’s Cardiovascular Health 2011, 185-189.

Dupouy J. Poutrain JC, Lapeyre-Mestre M. Naltrexone et traitement substitutif aux opiacés. Thérapie 2011. 66, 549-552.

Durrieu G, Caillet C, Lacroix I, Jacquet A, Faucher A, Ouaret S, Sommet A, Perault-Pochat MC, Kreft-Jais C, Castot A, Damase-Michel C, Montastruc JL, et le Réseau Français des centres de pharmacovigilance. Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Thérapie 2011, 66, 527-40.

Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre-Mestre M, Micallef J. Evidence of clonazepam abuse liability : results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam Clin Pharmacol 2011, 25, 633-41.

Fuzier R, Bataille B, Fuzier V, Richez AS, Maguès JP, Choquet O, Montastruc JL, Lapeyre-Mestre M. Spinal anesthesia failure after local anesthetic injection into cerebrospinal fluid. Regional Anesth and Pain Med 2011, 36, 322-26.

Galinier M, Lairez O, Roncalli J, Dumonteil N, Maury P, Pathak A, Biendel C. Cardiomyopathies dilatées primitives et secondaires. Cardiologie 2011, 11, 44.

Grossac J, Ruiz S, Bondon-Guitton E, Roux FE, Fourcade O, Montastruc JL, Geeraerts T. Severe intracranial bleeding related to vitamin K Antagonist-Ropinirole interaction. Mov Disord. 2011, 26, 1962-63.
Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet 2011, 378, 1543-4.

Hurault-Delarue C, Lacroix I, Vidal S, Montastruc JL, Damase-Michel C. Drugs in pregnancy : study in the EFEMERIS database (2004 to 2008). Gynecol Obstet Fertil 2011, 10, 554-8.

Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment : a systematic review. Br J Clin Pharmacol 2011, 71, 832-843.

Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre M. Cannabis-related hospitalizations : unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011, 71, 758-765.

Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women : a prospective multicenter study. Eur J Clin Pharmacol. 2011, 67, 1053-59.

Lacroix I, Damase-Michel C, Kreft-Jais C, Castot A, Montastruc JL. 2009 H1N1 influenza vaccines in pregnant women : the French Pharmacovigilance survey. Vaccine 2011, 7, 1357-8.

Lacroix I, Hurault-Delarue C, Kessler S, Guitard C, Vidal S, Albouy-Cossard C, Montastruc JL, Damase-Michel C. First epidemiologic data about phloroglucinol exposure during first trimester of pregnancy. Gynecol Obstet Fertil 2011, 39, 694-697.

Montastruc JL, Durrieu G, Rascol O. Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2011, 29 (11).

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and Strengths of the disproportionality analysis for identification of Adverse Drug Reactions in a PharmacoVigilance database. Br J Clin Pharmacol. 2011 72, 905-908.

Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL. Life-threatening drug-associated hyperkalemia : a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf 2011, 20,747-753.

Omon E, Damase-Michel C, Hurault-Delarue C, Lacroix I, Montastruc JL, Oustric S, Escourrou B. Non-adjuvanted 2009 influenza A (H1N1)v vaccine pregnant women : the results of a French prospective descriptive study. Vaccine 2011, 29, 9649-54.

Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E ; on behalf of the CESIR Research Group : Avalos M, Bazin F, Blazejewski S, Contrand B, Durrieu G, Girodet PO, Goldberg M, Laumon B, Lauque D, Lecoules N, Memes L, Merle L, Merlière Y, Montastruc JL, Noize P, Orsoni N, POariente A, Ribéreau-Gayon R, Salmi LR, Thiessard F, Tricotel A. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011, 89, 595-601.

Pauly V, Frauger E, Pradel V, Nordman S, Pourcel L, Natali F, SciortinoV, Lapeyre-Mestre M, Micallef J, Thirion X. Monitoring of benzodiazepine diversion using a multi-indicator approach. Psychopharmacol 2011, 26, 268-277.

Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation : prevalence, risk factors and pharmacovigilance data among methadone-treates patients in France. Fundam and Clin Pharmacol 2011.25, 503-510.

Pugnet G, Pathak A, Dumonteil N, Sailler L. Giant cell arteritis as a cause of acute myocarditis in the elderly. J Rhumatol 2011, 38, 2497.

Roulet L, Asseray N, Mottier ML, Chiffolleau A, Potel G, Lapeyre-Mestre M, Ballereau F. Consommation de jus de pamplemousse et risque d’interactions médicamenteuses : étude transversale dans un service d’urgences médicales. Thérapie 2011, 66, 421-429.

Rouve N, Bagheri H, Telmon N, Pathak A, Franchitto N, Schmitt L, Rougé D, Lapeyre-Mestre M, Montastruc JL. the French Association of Regional PharmacoVigilance Centres. Prescribed drugs and violence : a case/noncase study in the French PharmacoVigilance Database. Eur J Clin Pharmacol. 2011, 67, 1189-98.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puechal X, Wendling D, Lemann M, Ravaud P, Mariette X, Bagheri H, Blandin B, Breban M, Bretagne S, Castot A, Chichmanian RM, Chosidow O, Dautzenberg B, Dellamonica P, Dufeu-Demazes N, Emilie D, Gillet C, Hugot JP,Kreft Jais C, Leport C, Montastruc JL, Prieur AM, Ravaud P, Roux C, Vittecoq D. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective french RATIO registry. Ann Rheum Dis 2011, 70, 616.

Wagner S, Varet-Legros M, Fabre C, Montastruc JL, Bagheri H. Confounding factors for variation of clozapine plasma levels : drug interactions with proton pump inhibitor or infectious aetiologies ? Eur J Clin Pharmacol 2011, 67, 533-534.